- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | H.C. Wainwright reiterates Alto Neuroscience stock rating at buy | 1 | Investing.com | ||
| Mo | H.C. Wainwright hält an "Buy"-Rating für Alto Neuroscience fest | 1 | Investing.com Deutsch | ||
| 01.04. | Alto Neuroscience's ALTO-101 misses primary endpoint in trial | 4 | Investing.com | ||
| 01.04. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Stifel reiterates Buy on Alto Neuroscience stock, $33 target | 1 | Investing.com | ||
| 16.03. | Jefferies raises Alto Neuroscience stock price target on pipeline | 1 | Investing.com | ||
| 16.03. | Alto Neuroscience Shares Rise 9% After FY25 Results And $120 Mln Private Placement | - | RTTNews | ||
| ALTO NEUROSCIENCE Aktie jetzt für 0€ handeln | |||||
| 16.03. | Alto Neuroscience: $120 Million Raised To Advance Treatment-Resistant Depression Drug Candidate | 2 | pulse2.com | ||
| 16.03. | Alto Neuroscience announces $120M private placement financing | 1 | Seeking Alpha | ||
| 16.03. | Alto Neuroscience, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 16.03. | Alto Neuroscience GAAP EPS of -$2.19 beats by $0.06 | 2 | Seeking Alpha | ||
| 16.03. | Alto Neuroscience, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 16.03. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.02. | Alto Neuroscience completes enrollment in schizophrenia drug trial | 2 | Investing.com | ||
| 14.01. | Alto Neuroscience erhält US-Patent für Methode zur Depressionsbehandlung | 4 | Investing.com Deutsch | ||
| 14.01. | Alto Neuroscience receives patent for depression treatment method | 2 | Investing.com | ||
| 05.01. | Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating | 1 | Investing.com | ||
| 17.11.25 | This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | 1 | Benzinga.com | ||
| 17.11.25 | BTIG startet Coverage für Alto Neuroscience mit "Kaufen" - Präzisionspsychiatrie im Fokus | 3 | Investing.com Deutsch | ||
| 17.11.25 | Alto Neuroscience stock initiated at Buy by BTIG on precision psychiatry approach | 1 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,45 | -0,63 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| AMGEN | 306,25 | +2,15 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 7,290 | +0,97 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 151,28 | -1,89 % | Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,250 | +1,39 % | Where Will Viking Therapeutics Stock Be in 10 Years? | ||
| MAINZ BIOMED | 0,473 | -9,12 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| INTELLIA THERAPEUTICS | 11,820 | -0,67 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TEMPUS AI | 38,000 | -6,66 % | Trader-Interview mit Sascha Huber: Marvell Technology, Intuit, Salesforce, Tempus AI & MicroStrategy | In dieser Ausgabe des Trader-Interviews analysieren Andreas Bernstein und Sascha Huber die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit Fokus auf den Einfluss von Künstlicher Intelligenz... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,426 | +0,45 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 48,150 | -1,65 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 19,040 | +1,38 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen | |
| EXELIXIS | 38,375 | +1,27 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,200 | -4,50 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,120 | +1,63 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Year-End 2025 Update on Operations | Initiated pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen |
ALTO NEUROSCIENCE INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 22,275 Euro und damit +2,32 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALTO NEUROSCIENCE INC finden Sie auf Wallstreet Online.